Potential personalised therapy for a specific kind of pancreatic cancer
Australian researchers have identified a potentially treatable subtype of pancreatic cancer, which accounts for about 2% of new cases. This subtype expresses high levels of the HER2 gene. HER2-amplified breast and gastric cancers are currently treated with Herceptin. Pancreatic cancer is the fourth leading cause of cause of cancer death in Western societies, with a 5-year survival rate of less than 5%. It is a molecularly diverse disease, meaning that each tumour will respond only to specific treatments that target its unique molecular make-up...
Source: Health News from Medical News Today - Category: Consumer Health News Tags: Pancreatic Cancer Source Type: news
More News: Cancer | Cancer & Oncology | Gastric (Stomach) Cancer | Gastroenterology | Genetics | Health | HER2 | Herceptin | Pancreas | Pancreatic Cancer